Status:
COMPLETED
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study
Lead Sponsor:
Khoo Teck Puat Hospital
Conditions:
Diabetes
Eligibility:
All Genders
21-65 years
Phase:
PHASE4
Brief Summary
Gliclazide has greater glucose lowering efficacy than glibenclamide among type 2 diabetes mellitus patients with minor haplotype (K23/A1369) at the KCNJ11/ABCC gene locations.
Detailed Description
Sulphonylurea (SU) is a glucose-lowering agent used widely to treat type 2 diabetes mellitus (T2DM). SU promotes insulin secretion from the pancreatic islet beta cell via binding and inhibition of the...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Age 21-65
- HbA1c \>8.0% on two consecutive visits
Exclusion
- Currently taking insulin at a regime more complex than basal insulin
- Not willing to perform self-blood glucose monitoring (SBGM)
- Renal impairment i.e. eGFR\<50mls/min
- Pregnancy or unwilling to practice adequate contraception
- Taking other medications that may affect blood glucose e.g. systemic glucocorticoids.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT02201602
Start Date
August 1 2014
End Date
July 1 2016
Last Update
September 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Khoo Teck Puat Hospital
Singapore, Singapore, Singapore, 768828